{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:02:38Z","timestamp":1791669758049,"version":"4.3.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intravesical therapy (IVT), including Bacillus Calmette-Gu\u00e9rin (BCG), is the standard of care for high grade (HG) non-muscle invasive bladder cancer (NMIBC). Despite the use of IVT, many patients recur after treatment. The bladder microbiome and its role in disease processes has recently risen to prominence. We aim to characterize changes that occur in the bladder microbiome over the course of intravesical therapy and assess whether these changes correlate with outcomes in patients with NMIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with NMIBC undergoing induction BCG or intravesical therapy were prospectively enrolled from January 2019 to March 2020. Patients with clinical T2 or greater pathology or active urinary tract infection at enrollment were excluded. Twenty-nine patients had catheterized (bladder) urine samples collected prior to induction intravesical therapy and prior to each IVT instillation. Twenty-seven received BCG while 2 received intravesical gemcitabine. Bacteria were identified using 16S ribosomal RNA gene sequencing. Bladder microbiome changes were evaluated and differences between patients who recurred and patients who did not recur after IVT were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across the 29 patients analyzed, bacterial richness decreased significantly following intravesical therapy (Richness, P=0.01). Evenness and overall diversity did not change significantly (Pielou, P=0.62; Shannon, P=0.13). Patients who experienced recurrence had a higher relative abundance of\n                      <jats:italic>Aerococcus<\/jats:italic>\n                      in their urine (P&amp;lt;0.01), while those who did not recur had significantly more\n                      <jats:italic>Ureaplasma<\/jats:italic>\n                      (P=0.01) and\n                      <jats:italic>Escherichia\/Shigella<\/jats:italic>\n                      species (P=0.05). Patients with decreased levels of alpha diversity were more likely to fall within the non-recurrence cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      IVT for NMIBC appears to change the urinary microbiome by decreasing richness while not altering evenness or overall diversity. The presence of\n                      <jats:italic>Aerococcus<\/jats:italic>\n                      species may be predictive of a poor cancer response to IVT, while the presence of\n                      <jats:italic>Ureaplasma<\/jats:italic>\n                      and\n                      <jats:italic>Escherichia\/Shigella<\/jats:italic>\n                      may predict a favorable response to IVT. Further studies are warranted to elucidate and confirm the significance of changes in the bladder microbiome.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2023.1125809","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T09:24:15Z","timestamp":1680686655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Impact of intravesical Bacillus Calmette-Gu\u00e9rin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Christopher","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayeromi","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiten D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Rac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag P.","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Dornbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Bajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Halverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal N.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus L.","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gorbonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","article-title":"Gut microbiota modulation of chemotherapy efficacy and toxicity","volume":"14","author":"Alexander","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B2","article-title":"Intravesical therapy for bladder cancer","year":"2022","journal-title":"Am. Cancer Soc. - Intravesical Ther. Bladder Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.1038\/s41598-018-29054-w","article-title":"The urinary microbiome associated with bladder cancer","volume":"8","author":"Bucevic Popovic","year":"2018","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","article-title":"DADA2: High-resolution sample inference from illumina amplicon data","volume":"13","author":"Callahan","year":"2016","journal-title":"Nat. Methods"},{"key":"B5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40168-018-0605-2","article-title":"Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data","volume":"6","author":"Davis","year":"2018","journal-title":"Microbiome"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00192-018-3732-1","article-title":"Urinary symptoms are associated with certain urinary microbes in urogynecologic surgical patients","volume":"29","author":"Fok","year":"2018","journal-title":"Int. Urogynecol J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/RRU.S63447","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res. Rep. Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12859-017-1670-4","article-title":"A Bayesian taxonomic classification method for 16S rRNA gene sequences with improved species-level accuracy","volume":"18","author":"Gao","year":"2017","journal-title":"BMC Bioinf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/JCM.02876-13","article-title":"Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder","volume":"52","author":"Hilt","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1097\/JU.0000000000002056.04","article-title":"Pd42-04 tumor microbiome associated with BCG response in non-muscle invasive bladder cancer","volume":"206","author":"Knorr","year":"2021","journal-title":"J. Urol."},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000002538.01","article-title":"Pd12-01 bladder tumor microbiome may augment response to BCG in non-muscle invasive bladder cancer","volume":"207","author":"Knorr","year":"2022","journal-title":"J. Urol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus calmette-guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","author":"Lewis","year":"2000","journal-title":"Am. J. Physiology-Renal Physiol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/apm.13097","article-title":"The discovery of bacterial biofilm in patients with muscle invasive bladder cancer","volume":"129","author":"Nadler","year":"2021","journal-title":"APMIS."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e01283","DOI":"10.1128\/mBio.01283-14","article-title":"The female urinary microbiome: a comparison of women with and without urgency urinary incontinence","volume":"5","author":"Pearce","year":"2014","journal-title":"mBio."},{"key":"B19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00345-009-0383-3.1","article-title":"The present and future burden of urinary bladder cancer in the world","volume":"27","author":"Ploeg","year":"2009","journal-title":"World J. Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1128\/JCM.00044-16","article-title":"The clinical urine culture: Enhanced techniques improve detection of clinically relevant microorganisms","volume":"54","author":"Price","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"D590","DOI":"10.1093\/nar\/gks1219","article-title":"The SILVA ribosomal RNA gene database project: improved data processing and web-based tools","volume":"41","author":"Quast","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B24","author":"Skinner","year":"2013"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.423.26","article-title":"Association of the commensal urinary microbiome with response to bacillus calmette-gu\u00e9rin (BCG) immunotherapy in nonmuscle invasive bladder cancer","volume":"37","author":"Sweis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101097JU0000000000003189","DOI":"10.1097\/JU.0000000000003189","article-title":"Detection of bacteria in bladder mucosa of adult females","author":"Wolfe","year":"2023","journal-title":"J. Urol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1128\/JCM.05852-11","article-title":"Evidence of uncultivated bacteria in the adult female bladder","volume":"50","author":"Wolfe","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033865","article-title":"Evaluation of methods for the extraction and purification of DNA from the human microbiome","volume":"7","author":"Yuan","year":"2012","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.555508","article-title":"Alterations in urobiome in patients with bladder cancer and implications for clinical outcome: A single-institution study","volume":"10","author":"Zeng","year":"2020","journal-title":"Front. Cell Infect. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1125809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T09:24:21Z","timestamp":1680686661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1125809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":29,"alternative-id":["10.3389\/fcimb.2023.1125809"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1125809","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"article-number":"1125809"}}